TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial
- 1 December 2006
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet Neurology
- Vol. 5 (12), 1013-1020
- https://doi.org/10.1016/s1474-4422(06)70602-0
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neuronsAnnals of Neurology, 2006
- Reproducible nigral cell loss after systemic proteasomal inhibitor administration to ratsAnnals of Neurology, 2006
- Lack of nigrostriatal pathology in a rat model of proteasome inhibitionAnnals of Neurology, 2006
- Proteasome inhibition and Parkinson's disease modelingAnnals of Neurology, 2006
- Proteasome inhibitor-induced model of Parkinson's diseaseAnnals of Neurology, 2006
- Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeysAnnals of Neurology, 2006
- Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's diseaseAnnals of Neurology, 2004
- Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase BJournal of Neural Transmission, 2003
- Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1993
- ParkinsonismNeurology, 1967